NCT07612280
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07612280
Title Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Jubilant Therapeutics Inc.
Indications
Therapies
Age Groups: senior
Covered Countries AUS


No variant requirements are available.